Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Ginkgo biloba Extract Decreases Scopolamine-Induced Congophilic Amyloid Plaques Accumulation in Male Rat's Brain

Emsehgol Nikmahzar 1 , Mehrdad Jahanshahi 2 , * and Fatemeh Babakordi 1
Authors Information
1 Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2 Neuroscience Research Center, Department of Anatomy, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 30, 2018, 13 (4); e69143
  • Published Online: December 2, 2018
  • Article Type: Research Article
  • Received: February 6, 2017
  • Revised: April 7, 2018
  • Accepted: April 7, 2018
  • DOI: 10.5812/jjnpp.69143

To Cite: Nikmahzar E , Jahanshahi M, Babakordi F. Ginkgo biloba Extract Decreases Scopolamine-Induced Congophilic Amyloid Plaques Accumulation in Male Rat's Brain, Jundishapur J Nat Pharm Prod. 2018 ; 13(4):e69143. doi: 10.5812/jjnpp.69143.

Abstract
Copyright © 2018, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Muazzam Khan M, Ahsan F, Ahmad U, Akhtar J, Mujahid M; Badruddeen. Alzheimer disease: A review. World J Pharm Pharm Sci. 2016;5(6):649-66. doi: 10.20959/wjpps20166-7045.
  • 2. Heggland I, Storkaas IS, Soligard HT, Kobro-Flatmoen A, Witter MP. Stereological estimation of neuron number and plaque load in the hippocampal region of a transgenic rat model of Alzheimer's disease. Eur J Neurosci. 2015;41(9):1245-62. doi: 10.1111/ejn.12876. [PubMed: 25808554].
  • 3. Hsu PJ, Shou H, Benzinger T, Marcus D, Durbin T, Morris JC, et al. Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. J Alzheimers Dis. 2015;45(1):27-33. doi: 10.3233/JAD-141743. [PubMed: 25428255]. [PubMed Central: PMC4351157].
  • 4. Kaur R, Parveen S, Mehan S, Khanna D, Kalra S. Neuroprotective effect of ellagic acid against chronically scopolamine induced Alzheimer’s type memory and cognitive dysfunctions: Possible behavioural and biochemical evidences. Int J Preven Med Res. 2015;1:45-64.
  • 5. Liu X, Hao W, Qin Y, Decker Y, Wang X, Burkart M, et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. Brain Behav Immun. 2015;46:121-31. doi: 10.1016/j.bbi.2015.01.011. [PubMed: 25637484].
  • 6. Mohs RC. A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: Can they be reduced? Alzheimers Dement. 2008;4(1 Suppl 1):S85-7. doi: 10.1016/j.jalz.2007.11.011. [PubMed: 18632007].
  • 7. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007;21(4):292-9. doi: 10.1097/WAD.0b013e31815d1048. [PubMed: 18090435].
  • 8. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: The flat line of progress. Arch Med Res. 2012;43(8):694-8. doi: 10.1016/j.arcmed.2012.09.009. [PubMed: 23085451].
  • 9. Liu T, Xia Z, Zhang WW, Xu JR, Ge XX, Li J, et al. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. Pharmacol Biochem Behav. 2013;104:138-43. doi: 10.1016/j.pbb.2012.11.009. [PubMed: 23262302].
  • 10. Bihaqi SW, Singh AP, Tiwari M. Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and amyloid precursor protein (AbetaPP) expression in rat brain. Indian J Pharmacol. 2012;44(5):593-8. doi: 10.4103/0253-7613.100383. [PubMed: 23112420]. [PubMed Central: PMC3480791].
  • 11. Pachauri SD, Tota S, Khandelwal K, Verma PR, Nath C, Hanif K, et al. Protective effect of fruits of Morinda citrifolia L. on scopolamine induced memory impairment in mice: A behavioral, biochemical and cerebral blood flow study. J Ethnopharmacol. 2012;139(1):34-41. doi: 10.1016/j.jep.2011.09.057. [PubMed: 22107832].
  • 12. Wang X, Wang ZH, Wu YY, Tang H, Tan L, Wang X, et al. Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol Neurobiol. 2013;47(1):373-81. doi: 10.1007/s12035-012-8355-9. [PubMed: 23054680].
  • 13. Capurro V, Busquet P, Lopes JP, Bertorelli R, Tarozzo G, Bolognesi ML, et al. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One. 2013;8(2). e56870. doi: 10.1371/journal.pone.0056870. [PubMed: 23441223]. [PubMed Central: PMC3575497].
  • 14. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3). a006395. doi: 10.1101/cshperspect.a006395. [PubMed: 22393531]. [PubMed Central: PMC3282492].
  • 15. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, et al. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci. 2003;58(4):372-7. doi: 10.1093/gerona/58.4.M372. [PubMed: 12663701].
  • 16. Heinonen T, Gaus W. Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract. Toxicology. 2015;327:95-115. doi: 10.1016/j.tox.2014.10.013. [PubMed: 25446328].
  • 17. Kwon KJ, Lee EJ, Cho KS, Cho DH, Shin CY, Han SH. Ginkgo biloba extract (Egb761) attenuates zinc-induced tau phosphorylation at Ser262 by regulating GSK3beta activity in rat primary cortical neurons. Food Funct. 2015;6(6):2058-67. doi: 10.1039/c5fo00219b. [PubMed: 26032477].
  • 18. Jahanshahi M, Nickmahzar EG, Babakordi F. Effect of Gingko biloba extract on scopolamine-induced apoptosis in the hippocampus of rats. Anat Sci Int. 2013;88(4):217-22. doi: 10.1007/s12565-013-0188-8. [PubMed: 23828103].
  • 19. Seifhosseini S, Jahanshahi M, Moghimi A, Aazami NS. The effect of scopolamine on avoidance memory and hippocampal neurons in male wistar rats. Basic Clin Neurosci. 2011;3(1):9-15.
  • 20. Jahanshahi M, Sadeghi Y, Hosseini A. Estimation of astrocyte number in different subfield of rat hippocampus. Pak J Biolog Sci. 2006;9(8):1595-7.
  • 21. Lee B, Park J, Kwon S, Park MW, Oh SM, Yeom MJ, et al. Effect of wild ginseng on scopolamine-induced acetylcholine depletion in the rat hippocampus. J Pharm Pharmacol. 2010;62(2):263-71. doi: 10.1211/jpp.62.02.0015. [PubMed: 20487207].
  • 22. Jahanshahi M, Nickmahzar EG, Seif-Hoseini S, Babakordi F, Moharreri A. Scopolamine reduces the density of M1 muscarinic neurons in rats' hippocampus. Int J Morphol. 2013;31(4).
  • 23. Hosseini-Sharifabad M, Anvari M. Effects of Ginkgo biloba extract on the structure of Cornu ammonis in aged rat: A morphometric study. Iran J Basic Med Sci. 2015;18(9):932-7. [PubMed: 26523225]. [PubMed Central: PMC4620195].
  • 24. Rocher MN, Carre D, Spinnewyn B, Schulz J, Delaflotte S, Pignol B, et al. Long-term treatment with standardized Ginkgo biloba extract (EGb 761) attenuates cognitive deficits and hippocampal neuron loss in a gerbil model of vascular dementia. Fitoterapia. 2011;82(7):1075-80. doi: 10.1016/j.fitote.2011.07.001. [PubMed: 21820038].
  • 25. Choi DY, Lee YJ, Lee SY, Lee YM, Lee HH, Choi IS, et al. Attenuation of scopolamine-induced cognitive dysfunction by obovatol. Arch Pharm Res. 2012;35(7):1279-86. doi: 10.1007/s12272-012-0719-1. [PubMed: 22864751].
  • 26. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002;99(19):12197-202. doi: 10.1073/pnas.182425199. [PubMed: 12213959]. [PubMed Central: PMC129421].
  • 27. Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact. 2009;181(1):115-23. doi: 10.1016/j.cbi.2009.05.010. [PubMed: 19464278].
  • 28. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci. 2000;12(6):1882-90. doi: 10.1046/j.1460-9568.2000.00069.x. [PubMed: 10886329].
  • 29. Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis. 2003;5(4):287-300. doi: 10.3233/JAD-2003-5404. [PubMed: 14624024].
  • 30. Mullaicharam AR. A review on evidence based practice of Ginkgo biloba in brain health. Int J Chem Pharm Anal. 2013;1(1):24-30.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments